Inventor
GUDE MARKUS
CH28 patents
⚠️ This page may combine multiple inventors who share the name “GUDE MARKUS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AISSAOUI HAMED
8 patentsUS8236964B2Aug 7, 2012
Thiazolidine derivatives as orexin receptor antagonists
AISSAOUI HAMED13 citations84
US8106215B2Jan 31, 2012
3-aza-bicyclo[3.3.0]octane compounds
AISSAOUI HAMED13 citations84
US8288435B2Oct 16, 2012
2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
AISSAOUI HAMED11 citations83
US8288429B2Oct 16, 2012
2-aza-bicyclo[3.3.0]octane derivatives
AISSAOUI HAMED15 citations83
US8063099B2Nov 22, 2011
Trans-3-aza-bicyclo[3.1.0]hexane derivatives
AISSAOUI HAMED7 citations82
US8188082B2May 29, 2012
5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives
AISSAOUI HAMED8 citations78
US8133901B2Mar 13, 2012
3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
AISSAOUI HAMED4 citations62
US8329706B2Dec 11, 2012
Oxazolidinone derivatives
AISSAOUI HAMED1 citations51
IDORSIA PHARMACEUTICALS LTD
7 patentsUS9732075B2Aug 15, 2017
Benzimidazole-proline derivatives
IDORSIA PHARMACEUTICALS LTD8 citations82
US10329287B2Jun 25, 2019
Benzimidazole-proline derivatives
IDORSIA PHARMACEUTICALS LTD3 citations72
US10023560B2Jul 17, 2018
Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
IDORSIA PHARMACEUTICALS LTD3 citations72
US9914720B2Mar 13, 2018
Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
IDORSIA PHARMACEUTICALS LTD3 citations72
US9790208B2Oct 17, 2017
Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
IDORSIA PHARMACEUTICALS LTD4 citations72
US9914721B2Mar 13, 2018
Use of benzimidazole-proline derivatives
IDORSIA PHARMACEUTICALS LTD4 citations71
US11040966B2Jun 22, 2021
Benzimidazole-proline derivatives
IDORSIA PHARMACEUTICALS LTD0 citations60
ACTELION PHARMACEUTICALS LTD
6 patentsUS7994336B2Aug 9, 2011
Azetidine compounds as orexin receptor antagonists
ACTELION PHARMACEUTICALS LTD23 citations92
US8003654B2Aug 23, 2011
N-glycinsulfonamide derivatives and uses as orexin receptor antagonists
ACTELION PHARMACEUTICALS LTD7 citations84
US7834028B2Nov 16, 2010
Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
ACTELION PHARMACEUTICALS LTD9 citations84
US9493446B2Nov 15, 2016
Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
ACTELION PHARMACEUTICALS LTD6 citations73
US9428456B2Aug 30, 2016
1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
ACTELION PHARMACEUTICALS LTD3 citations70
US9211279B2Dec 15, 2015
Proline sulfonamide derivatives as orexin receptor antagonists
ACTELION PHARMACEUTICALS LTD3 citations62